Jacobio Pharmaceuticals Group Future Growth
Future criteria checks 0/6
Jacobio Pharmaceuticals Group's revenue is forecast to decline at 2.4% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 43.4% |
Revenue growth rate | -2.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 02 Sep 2024 |
Recent future growth updates
Recent updates
Does Jacobio Pharmaceuticals Group (HKG:1167) Have A Healthy Balance Sheet?
Nov 24Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation
May 31Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?
May 29We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely
May 10Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook
Aug 26We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate
Jul 29We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth
Apr 29What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?
Mar 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 74 | N/A | N/A | N/A | 1 |
12/31/2025 | 107 | N/A | N/A | N/A | 1 |
12/31/2024 | 200 | N/A | N/A | N/A | 1 |
6/30/2024 | 23 | -362 | -334 | -325 | N/A |
3/31/2024 | 43 | -361 | -369 | -345 | N/A |
12/31/2023 | 64 | -359 | -403 | -364 | N/A |
9/30/2023 | 72 | -385 | -426 | -382 | N/A |
6/30/2023 | 81 | -410 | -449 | -400 | N/A |
3/31/2023 | 89 | -391 | -379 | -346 | N/A |
12/31/2022 | 96 | -372 | -309 | -292 | N/A |
9/30/2022 | 123 | -332 | -230 | -218 | N/A |
6/30/2022 | 150 | -292 | -151 | -145 | N/A |
3/31/2022 | 151 | -297 | -155 | -146 | N/A |
12/31/2021 | 153 | -301 | -159 | -147 | N/A |
9/30/2021 | 348 | -570 | -70 | -56 | N/A |
6/30/2021 | 544 | -839 | 18 | 36 | N/A |
3/31/2021 | 515 | -1,177 | 43 | 57 | N/A |
12/31/2020 | 486 | -1,514 | 68 | 79 | N/A |
9/30/2020 | 243 | -1,298 | -37 | -30 | N/A |
6/30/2020 | N/A | -1,082 | -141 | -139 | N/A |
3/31/2020 | N/A | -753 | -129 | -126 | N/A |
12/31/2019 | N/A | -425 | -116 | -113 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 1167's forecast earnings growth is above the savings rate (2.3%).
Earnings vs Market: Insufficient data to determine if 1167's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 1167's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 1167's revenue is expected to decline over the next 3 years (-2.4% per year).
High Growth Revenue: 1167's revenue is forecast to decline over the next 3 years (-2.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1167's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 05:59 |
End of Day Share Price | 2024/12/20 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Jacobio Pharmaceuticals Group Co., Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Ziyi Chen | Goldman Sachs |